Navigation Links
Pharmacopeia To Present at BMO Capital Markets' Seventh Annual Focus on Healthcare Conference
Date:11/26/2007

PRINCETON, N.J., Nov. 26 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced that Dr. Leslie J. Browne, President and Chief Executive Officer, will deliver a corporate presentation at the seventh annual Focus on Healthcare Conference hosted by BMO Capital Markets. The conference will be held December 4-5, 2007, at the Millennium Broadway Hotel in New York City.

Dr. Browne's presentation will take place at 3:30 p.m. EST on Tuesday, December 4th. The presentation will include an overview of the company's drug development pipeline, including an update on its clinical studies with PS433540 (DARA) and the recently acquired PS178990 (SARM) program, recent corporate accomplishments and upcoming milestones. A live webcast of the presentation can be accessed at http://www.bmocm.com/conferences/2007healthcare/.

ABOUT PHARMACOPEIA

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or by partners including seven clinical compounds in Phase 2 or Phase 1 development addressing hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic agreements with major pharmaceutical and biotechnology companies, including Bristol
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
3. Avicena Group to Present at Noble Financial Conference
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. CEL-SCI to Present at the Noble Financial Conference
8. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
9. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
10. Strategic Diagnostics Updates Roth Conference Presentation Time
11. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 PuraMed BioScience ® , ... of over-the-counter (OTC) medicinal and healthcare products, announced ... the company based on low market capitalization valuation. ... All Natural Product to Treat Migraine Headaches ... Prescription Competitor , Currently Available Nationwide at ...
(Date:5/23/2013)... HILLS, Calif. , May 23, 2013  Saddleback ... recently became the first hospital on the ... robotic technology. This new surgical option provides women with ... Marc Winter , M.D., ... gynecologist and surgeon and medical director of minimally invasive ...
(Date:5/23/2013)... 2013 Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced ... year,s American Society Of Clinical Oncology (ASCO) meeting in ... role in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ... the pre-eminent conference focused on clinical treatment of cancer, ...
(Date:5/23/2013)... 23, 2013 Pusan National University Yangsan ... biotherapeutics and contract research company focused on research ... announced today a publication reporting the induction of ... oncolytic and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; Jennerex ... in the May 15 th , 2013 issue ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... 8 Beckman Coulter, Inc. (NYSE: ... of products that simplify, automate, and innovate complex ... Coulter,s chairman, president and chief executive officer, will ... Lynch Healthcare Conference on Wednesday, May 13, 2009 ...
... Yongye Biotechnology,International, Inc. (OTC Bulletin Board: YGYB, ... distributor of plant and animal nutrient products ... that it closed a private placement,financing with ... of the same investors who participated in ...
... 8 PharmAthene, Inc. (NYSE Amex: PIP ... and chemical threats, announced a date change for its ... 2009 financial results will now be released on Friday, ... call to discuss its first quarter 2009 financial results. ...
Cached Biology Technology:Yongye Biotechnology International Raises $ 9.0 Million In Private Placement, Raises Guidance 2Yongye Biotechnology International Raises $ 9.0 Million In Private Placement, Raises Guidance 3
(Date:5/24/2013)... of 500 leading water scientists from around the world ... "in the short span of one or two generations, ... will be living under the handicap of severe pressure ... which there is no substitute. This handicap will be ... scientists bluntly pointed to chronic underlying problems led by ...
(Date:5/23/2013)... RICHLAND, Wash. Pacific Northwest National Laboratory honored ... and commercialization of intellectual property at PNNL,s annual ... , The Department of Energy national laboratory ... Year for his work developing battery materials that ... to the electrical grid, and reduce the time ...
(Date:5/23/2013)... suppresses lipid synthesis in the liver, UC Irvine endocrinologists ... liver diseases. , With this finding, Dr. Ellis ... in the field. Study results appear in the May ... , "The dogma in the steroid receptor field for ... the nucleus respond to steroid hormones by regulating genes ...
Breaking Biology News(10 mins):A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 3A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 4PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2
... cancer, including stomach, liver and colon, are far more common ... differences in lifestyle, such as diet and smoking, may account ... are rooted in basic biological differences between men and women. ... shows that treating male mice with estrogen dramatically lowers their ...
... giant seaweeds, are spreading fast, with harmful effects on ... the Mediterranean seabed. Some native species, such as sea ... invasion, but only during its early stages, or when ... carried out a study to look at the ability ...
... If genetically modified Atlantic salmon were to escape ... their genes into the wild, Canadian researchers have found. ... the potential reproductive implications of GM salmon as they ... of growth-enhancing transgenic technologies has long been of interest ...
Cached Biology News:Study explains why men are at higher risk for stomach cancer 2Study explains why men are at higher risk for stomach cancer 3Sea urchins cannot control invasive seaweeds 2First study into GM Atlantic salmon mating reveals danger of escape to wild gene pool 2
The Captivate Disposable Sample Chamber is designed for use with the Captivate magnetic yoke assembly (C-24700) and can be used with our Captivate ferrofluid conjugates (C-21473 C-21474 C-21476) or ...
MOUSE ANTI HUMAN MOC31:AZIDE FREE...
... mycobacteria in Complete Freund's adjuvant attract macrophages ... which enhances the immuneresponse. For this reason, ... the initial injections; Incomplete Freund's adjuvant is ... in saline) are typically mixed with an ...
HiTrap Streptavidin HP, 5 x 1 ml. Category: Chromatography Systems & Accessories, Systems....
Biology Products: